Business
Bolt Biotherapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
BDC-4182 Phase 1 dose-escalation study now open for enrollment BDC-3042 Phase 1 dose-esca...
About this update from Bolt Metals Corp.
[{"type":"text","content":"Bolt Biotherapeutics Reports First Quarter 2025 Financial Results and Provides Business Update\n\n\n\n\n\n BDC-4182 Phase 1 dose-escalation study now open for enrollment\n \n\n\n\n BDC-3042 Phase 1 dose-escalation data presented at AACR 2025 demonstrated a favorable safety profile, dose-dependent biological activity, and monotherapy anti-tumor activity\n \n\n\n\n Bolt is running a partnering process to advance development of BDC-3042\n \n\n\n\n Cash balance of $58.0 million as of March 31, 2025 anticipated to fund key milestones through mid-2026\n \n\n\n\n REDWOOD CITY, Calif., May 12, 2025 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today reported financial results for the first quarter ended March 31, 2025, and provided a business update.\n \n\n “We continue to make progress advancing our pipeline of first-in-class, novel immunotherapies,” said Willie Quinn, Chief Executive Officer. “We recently presented promising early clinical data for BDC-3042 at AACR and launched a process to find a partner to accelerate BDC-3042 development. We also just opened enrollment for the first next-generation Boltbody™ ISAC in our pipeline, BDC-4182. We are excited to see what our ISAC platform technology can do for gastric and gastroesophageal cancer patients. We continue to be good stewards of capital as we execute against our mission to deliver new treatment options to patients with cancer.”\n \n\n\n Recent Highlights and Anticipated Milestones\n \n\n\n\n\n Clinical data from Phase 1 dose-escalation study of BDC-3042 presented at AACR Annual Meeting 2025\n \n in April 2025. BDC-3042 is a proprietary agonist antibody that targets dectin-2, an immune-activating receptor expressed by tumor-associated macrophages (TAMs). This single-agent, dose-escalation Phase 1 clinical study is evaluating BDC-3042 in patients with metastatic or unresectable solid tumors including non-small cell lung cancer (NSCLC). The dose-escalation data support the selection of 10 mg/kg q2w as a recommended Phase 2 dose (RP2D), alongside potential exploration of other doses and schedules. The results support further clinical development in NSCLC and other post-immunotherapy settings, as patients previously treated...